Obalon Therapeutics

General Information

We are a commercial-stage medical device company focused on developing and commercializing innovative medical devices to treat obese and overweight people by facilitating weight loss. Our initial product offering is the Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. We recently received premarket approval, or PMA, from the U.S. Food and Drug Administration, or FDA, to market our balloon system for temporary use to facilitate weight loss in obese adults with a body mass index, or BMI, of 30 to 40, who have failed to lose weight through diet and exercise. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program.

Employees: 51
Founded: 2008
Contact Information
Address 5421 Avenida Encinas, Suite F Carlsbad, CA 92008, US
Phone Number (760) 795-6558
Web Address https://www.obalon.com
View Prospectus: Obalon Therapeutics
Financial Information
Market Cap $239.3mil
Revenues $3.9 mil (last 12 months)
Net Income $-16.1 mil (last 12 months)
IPO Profile
Symbol OBLN
Exchange NASDAQ
Shares (millions): 5.0
Price range $15.00 - $15.00
Est. $ Volume $75.0 mil
Manager / Joint Managers UBS Investment Bank/ Canaccord Genuity/ Stifel
CO-Managers BTIG
Expected To Trade: 10/6/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change